-
Clearside Stock Plummets After Company Hints At Complete Response Letter For Macular Edema Drug
Thursday, August 22, 2019 - 11:20am | 477Clearside Biomedical Inc (NASDAQ: CLSD) shares entered penny stock territory Thursday after the company issued an update on what transpired at a meeting with the FDA regarding the new drug application for Xipere. What Happened In a meeting this week, the FDA's Office of...
-
Clearside Biomedical Plunges 60% Following Phase 3 Study Results
Monday, November 5, 2018 - 4:40pm | 324Shares of Clearside Biomedical Inc (NASDAQ: CLSD), a biopharmaceutical company that focuses on the treatment of serious eye diseases, plunged 60 percent Monday after announcing disappointing results from a Phase 3 study. What Happened Clearside said in a press release its Phase 3 clinical...